Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 9:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 2,554 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Melphalan, Prednisone, Thalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
234
States / cities
Birmingham, Alabama • Casa Grande, Arizona • Sedona, Arizona + 205 more
Completed Phase 3 Interventional Results available

TAXUS PERSEUS Workhorse

NCT00484315
Conditions
Coronary Artery Disease
Interventions
Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation, Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
82
States / cities
Birmingham, Alabama • Bakersfield, California • La Jolla, California + 67 more
Conditions
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Interventions
RO7198457 intravenous (IV), Observational group (no intervention)
Drug · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Greenbrae, California • Indianapolis, Indiana • Minneapolis, Minnesota + 12 more
Conditions
NSCLC, Non-small Cell Lung Cancer, Lung Cancer
Interventions
MEDI4736, tremelimumab
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
28
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
Conditions
Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
Interventions
Indoximod, Temozolomide, Bevacizumab, Stereotactic Radiation
Drug · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
16 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
17
States / cities
Castro Valley, California • Los Angeles, California • Orange, California + 14 more
Conditions
Post-operative Pain, Acute, Cesarean Section, Opioid Use Disorder, Opioids; Harmful Use
Interventions
Auricular percutaneous nerve field stimulator, Sham auricular percutaneous nerve field stimulator
Device
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Falls Church, Virginia
Conditions
Sedation
Interventions
fospropofol disodium Subgroup 1 Lower Dose, fospropofol disodium Subgroup 1 Approved Dose, fospropofol disodium Subgroup 2 Lower Dose, fospropofol disodium Subgroup 2 Approved Dose, fospropofol disodium Subgroup 3 Lower Dose, fospropofol disodium Subgroup 3 Approved Dose
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
23
States / cities
Phoenix, Arizona • Baldwin Park, California • San Diego, California + 20 more
Conditions
Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
Interventions
DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Chemotherapy
Biological · Radiation · Drug
Lead sponsor
DEKA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Duarte, California • Manhasset, New York • Oklahoma City, Oklahoma + 3 more
Conditions
Renal Failure Chronic Requiring Hemodialysis
Interventions
Soluble Ferric Pyrophosphate (SFP), Standard dialysate
Drug · Device
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
38
States / cities
Paragould, Arkansas • Pine Bluff, Arkansas • Alhambra, California + 31 more
Approved For Marketing No phase listed Expanded access

Afatinib Expanded Access Program

NCT01649284
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
afatinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
66
States / cities
Mobile, Alabama • Goodyear, Arizona • Hot Springs, Arkansas + 59 more
Conditions
Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan (Dato-DXd), Steroid Containing Mouthwash, Non-Steroid Containing Mouthwash
Drug · Other
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more
Conditions
Euvolemic Hyponatremia, Hypervolemic Hyponatremia
Interventions
Not listed
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
5,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
72
States / cities
Azusa, California • Inglewood, California • Los Angeles, California + 58 more
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
Interventions
Combination of varlilumab and nivolumab
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more
Conditions
HIV-1
Interventions
TMC125
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
182
States / cities
Anniston, Alabama • Birmingham, Alabama • Flagstaff, Arizona + 179 more
Conditions
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic, ccRCC, VHL-Associated Clear Cell Renal Cell Carcinoma, VHL-Associated Renal Cell Carcinoma, Kidney Cancer Metastatic, Kidney Cancers
Interventions
NEO-811
Drug
Lead sponsor
Neomorph, Inc
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Duarte, California • San Diego, California • New Haven, Connecticut + 11 more
Conditions
Diabetic Macular Edema
Interventions
RO7497372
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 34 more
Conditions
Pulmonary Hypertension
Interventions
Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo
Drug · Other
Lead sponsor
United Therapeutics
Industry
Eligibility
12 Years to 75 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Conditions
Non-Hodgkin's Lymphoma
Interventions
Rituximab, Aldesleukin
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Timeline
2005 – 2007
U.S. locations
21
States / cities
Denver, Colorado • Chicago, Illinois • Niles, Illinois + 18 more
Conditions
Lymphoma
Interventions
rituximab
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
483
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 328 more
Conditions
Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome
Interventions
AMX-883, Posaconazole
Drug
Lead sponsor
Amphista Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Fairfax, Virginia
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Osimertinib, Lazertinib, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,074 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
20
States / cities
Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more
Conditions
Mitral Valve Regurgitation
Interventions
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2036
U.S. locations
78
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 57 more
Conditions
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
Avacopan, Placebo, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
62
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Surprise, Arizona + 57 more
Conditions
Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Duarte, California • Irvine, California • Long Beach, California + 13 more